Interaction of Alkannin with CPEB4 Contributes to Its Antitumor Effects in Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Melanoma is an aggressive cancer with high metastatic potential.
• Cytoplasmic Polyadenylation Element Binding Protein 4 (CPEB4) is implicated in melanoma progression and is a potential therapeutic target.
• Alkannin exhibits antitumor activity, but its in vivo effects and molecular interactions in melanoma are not fully understood.

Purpose of the Study:

• To evaluate the in vivo antitumor efficacy of alkannin in a melanoma xenograft model.
• To investigate the direct molecular interaction between alkannin and CPEB4.
• To elucidate the downstream molecular mechanisms of alkannin's action in melanoma cells.

Main Methods:

• Subcutaneous xenograft model in BALB/c nude mice.
• Western blotting for CPEB4 expression.
• Drug Affinity Responsive Target Stability (DARTS), Cellular Thermal Shift Assay (CETSA), and Surface Plasmon Resonance (SPR) for molecular interaction studies.
• Establishment of stable CPEB4-knockdown A375 melanoma cells.
• Analysis of cell proliferation, apoptosis, cell cycle, migration, invasion, and signaling molecules.

Main Results:

• Alkannin significantly suppressed tumor growth in vivo and reduced CPEB4 expression dose-dependently.
• DARTS and CETSA indicated alkannin-induced stabilization of CPEB4.
• SPR confirmed a direct physical interaction between alkannin and CPEB4 with micromolar affinity.
• Alkannin downregulated CPEB4 and PRC1; CPEB4 knockdown suppressed MITF and PRC1.
• Alkannin did not significantly alter MITF expression alone under experimental conditions.

Conclusions:

• Alkannin demonstrates significant antitumor activity against melanoma in vivo.
• The direct interaction between alkannin and CPEB4 contributes to its therapeutic effects.
• Alkannin's action involves modulation of CPEB4, PRC1, and potentially MITF, affecting melanoma cell proliferation, survival, migration, and invasion.